An effective approach to screen HCC in patients at a higher risk is 6-month abdominal ultrasound accompanied or not by alpha-fetoprotein dosage.[20,21] Surveillance for cholangiocarcinoma remains a challenge as there is no consensus among experts. The gene discussed is AFP; the disease is hepatocellular carcinoma.